Technology
Dostarlimab Yields Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
CancerNetwork·14 hours ago·Global·1 min read
Source: CancerNetwork
Dostarlimab (Jemperli) monotherapy produced a clinically meaningful and sustained clinical complete response (cCR) rate at 12 months in patients with stage II/III mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanc... [3950 chars]
Related news
Technology
OpenAI’s feud with xAI carries on as Apple secrets fight revs up
thehindubusinessline.com
Technology
Okta, Inc. (OKTA) Discusses Technology Vision and Identity Security Strategy Transcript
seekingalpha.com
Technology
SBI Funds IPO: Brokerages recommend subscribing despite premium valuation
thehindubusinessline.com
Technology
Aon Highlights Maturing Transaction Risk Market in Asia Pacific Region as Claims Trends Evolve
manilatimes.net
Technology
The Trade Desk Unlocks Activation of Convenience Store Retail Data for Digital Advertising in Japan
thehindubusinessline.com
Technology
C of E’s £100m plan to address historical links to slavery faces legal challenge
www.theguardian.com